EMA should stop selling scientific advice to pharmaceutical industry
HAI Europe, the International Society of Drug Bulletins, the Medicines in Europe Forum and the Association Internationale de la Mutualité urged the European Medicines Agency (EMA) for providing confidential “advice” to pharmaceutical companies on their development plans for new medicines in exchange for fees—a potentially harmful practice that the EMA is now trying to extend to national health technology assessment (HTA) bodies in the European Union. Read more in our joint response to the EMA’s public consultation on ‘Best practice guidance for pilot EMA HTA parallel scientific advice procedures’ and press release.
Investor-to-state dispute settlement in EU-US trade agreement risks access to affordable medicines
HAI Europe, along with several other European and American NGOs, publicly criticised the inclusion of 'investor-to-state dispute settlement' in the Transatlantic Trade and Investment Partnership (TTIP), warning that it will undermine public health policies of European Union Member States and severely jeopardise access to affordable medicines and public health protection. To learn more, read our joint press release and response to the European Commission's public consultation on the issue.
True commitment to transparency needed in EMA's policy on clinical trial data
HAI Europe continues pressing the European Medicines Agency not to backtrack on its commitments to clinical trial data transparency. The Agency is expected to formally adopt its new clinical trial data policy at its next management board meeting on 2 October. HAI Europe, along with other health and transparency advocates, as well as the European Ombudsman, have publicly expressed concerns that the Agency's policy will restrict public access to clinical trial data. Read more about it in our recent statement and blog post.